HC Wainwright Reaffirms "Buy" Rating for Pyxis Oncology (NASDAQ:PYXS)

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Pyxis Oncology (NASDAQ:PYXS - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock. HC Wainwright's price objective points to a potential upside of 273.13% from the stock's previous close. HC Wainwright also issued estimates for Pyxis Oncology's Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.42) EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at $0.33 EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.35) EPS, FY2027 earnings at ($1.28) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at $0.20 EPS.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS traded up $0.02 on Tuesday, hitting $1.34. The company's stock had a trading volume of 1,333,169 shares, compared to its average volume of 406,891. The company has a market capitalization of $83.11 million, a price-to-earnings ratio of -0.84 and a beta of 1.13. The stock's 50-day moving average is $1.16 and its two-hundred day moving average is $1.15. Pyxis Oncology has a 12 month low of $0.8332 and a 12 month high of $5.3899.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The company had revenue of $2.82 million during the quarter. Equities analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PYXS. Millennium Management LLC boosted its position in shares of Pyxis Oncology by 53.8% during the fourth quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock worth $4,650,000 after buying an additional 1,043,228 shares during the period. Jacobs Levy Equity Management Inc. raised its position in shares of Pyxis Oncology by 57.2% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 601,940 shares of the company's stock worth $939,000 after acquiring an additional 219,100 shares in the last quarter. 683 Capital Management LLC increased its position in Pyxis Oncology by 32.5% in the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company's stock valued at $539,000 after buying an additional 135,000 shares in the last quarter. Pier 88 Investment Partners LLC grew its holdings in shares of Pyxis Oncology by 296.6% in the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock valued at $383,000 after acquiring an additional 292,370 shares in the last quarter. Finally, Ridgeback Capital Investments L.P. purchased a new position in Pyxis Oncology in the fourth quarter valued at approximately $560,000. Institutional investors own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.